Publication | Closed Access

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Interleukin 2Autoimmune DiseaseAnti-gd2 Antibody Ch14.18/choImmunologyPathologyImmune SurveillanceAutoimmunityImmunotherapyMedicineHigh-risk Neuroblastoma